Effects of 2-(1-hydroxypentyl)-benzoate on platelet aggregation and thrombus formation in rats

Drug Development Research

Volumn 63, Issue 4, 2004, Pages 174-180

  Zhang, Yi ^a   Wang, Ling ^a   Zhang, Liying ^a   Wang, Xiaoliang ^a  

^a PEKING UNION MEDICAL COLLEGE   (China)

Author keywords

2 (1 hydroxypentyl) benzoate (dl PHPB); Cerebral ischemia; Platelet aggregation; Thrombus formation

Indexed keywords

2 (1 HYDROXYPENTYL)BENZOATE; 3 BUTYLPHTHALIDE; ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; ARACHIDONIC ACID; BENZOIC ACID DERIVATIVE; COLLAGEN; NEW DRUG; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL MODEL; ANTICOAGULATION; ARTERIOVENOUS SHUNT; ARTICLE; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACTIVITY; DRUG POTENCY; DRUG STRUCTURE; EX VIVO STUDY; IN VIVO STUDY; MALE; NONHUMAN; RAT; THROMBOCYTE AGGREGATION; THROMBOCYTE AGGREGATION INHIBITION; THROMBOGENESIS;

EID: 16344396144     PISSN: 02724391     EISSN: None     Source Type: Journal    
DOI: 10.1002/ddr.10401     Document Type: Article

References (24)

1. Becker RC. 1991. Seminars in thrombosis, thrombolysis and vascular biology. Cardiology 79:49-63.
2. Born GV. 1962. Aggregation of blood platelets by adenosine diphosphate and its reversal. Nature 194:927-929.
3. Chong ZZ, Feng YP. 1997. Effects of dl-3-n-butylphthalide on production of TXB2 and 6-keto-PGF1 alpha in rat brain during focal cerebral ischemia and reperfusion. Acta Pharmacol Sin 18:505-508.
4. Damiano BP, Mitchell JA, Giardino E, Corcoran T, Haertlein BJ, de Garavilla L, Kauffman JA, Hoekstra WJ, Maryanoff BE, Andrade-Gordon P. 2001. Antiplatelet and antithrombotic activity of RWJ-53308, a novel orally active glycoprotein IIb/IIIa antagonist. Thromb Res 104:113-26.
5. Dirnagl U, Iadecola C, Moskowitz MA. 1999. Pathobiology of ischaemic stroke: an integrated view. Trends Neurosci 22:391-397.
6. Dong GX, Feng YP. 2002. Effects of NBP on ATPase and antioxidant enzymes activities and lipid peroxidation in transient focal cerebral ischemic rats. Acta Acad Med Sinicae 24:93-97.
7. Hiroyuki N, Hiroaki N, Yasumichi I, Hisao T, Minoru S. 1996. In vivo evaluation of antiplatelet agents in gerbil model of carotid artery thrombosis. Stroke 27:1099-1104.
8. Hoffmann P, Bernat A, Savi P Herbert JM. 1997. Antiplatelet and antithromboticefficacy of SR 121787, a nonpeptide orally active glycoprotein IIb/IIIa anagonist, in Rabbits: comparison with clopidogrel and aspirin. J Cardiovasc Pharmacol 30:360-366.
9. Hoffmann P, Bernat A, Savi P, Herbert JM. 1998. Prevention of thrombosis and enhancement of thrombolysis in the rabbits by SR 121787, a glycoprotein IIb/IIIa anagonist. J Pharmacol Exp Ther 286:670-675.
10. Hollopeter G, Jantzen HM, Vincent D, Li G, England L, Ramakrishnan V, Yang RB, Nurden P, Nurden A, Julius D, Conley PB. 2001. Identification of the platelet ADP receptor targeted by antithrombotic drugs. Nature 409:202-207.
11. Hou ST, MacManus JP 2002. Molecular mechanisms of cerebral ischemia-induced neuronal death. Int Rev Cytol 221:93-147.
12. Jorgensen MB, Diemer NH. 1982. Selective neuron loss after cerebral ischemia in die rat: possible role of transmitter glutamate. Acta Neurol Scand 66:536-546.
13. Kaul S, Makkar RR, Nakamura M, Litvack FI, Shah PK, Forrester JS, Hutsell TC, Eigler NL. 1996. Inhibition of acute stent thrombosis under high-shear flow conditions by a nitric oxide donor, DMHD/NO. An ex vivo porcine arteriovenous shunt study. Circulation 94:2228-2234.
14. Lanas AI, Arroyo MT, Esteva F, Cornudella R, Hirschowitz BT, Saina R. 1996. Aspirin related gastrointestinal bleeders have an exaggerated bleeding time response due to aspirin use. Gut 39:654-660.
15. Masamitsu S, Yoshiharu T, Kazuo U, Mitsuyoshi N. 1997. Antithrombotic effects of KBT-3022, a novel antiplatelet agent, in an arterial thrombosis model in the guinea-pig. Drug Develop Res 40:217-222.
16. Molina V, Arruzazabala ML, Carbajal D, Mas R, Valdes S. 2000. Antiplatelet and antithrombotic effect of D-003. Pharmacol Res 42:137-143.
17. Peng Y, Zeng XG, Feng YP, Wang XL. 2004. Antiplatelet and antithrombotic activity of L-3-butylphthalide in rats. J Cardiovasc Pharmacol 43:876-881.
18. Peters RF, Lees CM, Mitchell KA, Tweed MF, Talbot MD, Wallis RB. 1991. The characterisation of thrombus development in an improved model of arterio-venous shunt thrombosis in the rat and the effects of recombinant desulphatohirudin, heparin, and iloprost. Thromb Haemost 65:268-274.
19. Toshihiko I, Hideki K, Masaru T 1995. Platelet activation in the cerebral circulation in different subtypes of ischemic stroke and Binswanger's Disease. Stroke 26:52-56.
20. Umar A, Guerin V, Renard M, Boisseau M. Carreau C, Begaud B, Molimard M, Moore N. 2003. Effects of armagnac extracts on human platelet function in vitro and on rat arteriovenous shunt thrombosis in vivo. Thromb Res 110:135-140.
21. Xu HL, Feng YP. 2000. Inhibitory effects of chiral 3-n-butylphthalide on inflammation following focal ischemic brain injury in rats. Acta Pharmacol Sin 21:433-438.
22. Xu HL, Feng YP. 2001. Effects of 3-n-butylphthalide on thrombosis formation and platelet function in rats. Acta Pharm Sin 36:329-333.
23. Yan CT, Feng YP, Zhang JT. 1998. Effects of dl-3-n-butylphthalide on regional cerebral blood flow in right middle cerebral artery occlusion rats. Acta Pharmacol Sin Mar 19:117-120.
24. Yang JH, Wang XL, Xu ZB, Peng Y. 2002. Novel salts of 2-(α-hydroxypentyl) benzoic acid, the methods for preparation and the application of these salts (patent). PCT/CN02/00320.